Hancock Whitney Corp Bristol Myers Squibb CO Transaction History

Hancock Whitney Corp

$2.88 Billion
Q1 2024

A detailed history of Hancock Whitney Corp transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Hancock Whitney Corp holds 24,555 shares of BMY stock, worth $973,851. This represents 0.05% of its overall portfolio holdings.

Number of Shares

24,555

Previous 23,190 5.89%

Holding current value

$973,851

Previous $1.19 Million 11.94%

% of portfolio

0.05%

Previous 0.04%

31 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 16, 2024	BUY	$47.98 - $54.4 $65,492 - $74,256	1,365 Added 5.89%	24,555 $1.33 Million
Q4 2023 Feb 14, 2024	SELL	$48.48 - $57.85 $193,435 - $230,821	-3,990 Reduced 14.68%	23,190 $1.19 Million
Q3 2023 Nov 13, 2023	SELL	$57.89 - $64.73 $39,423 - $44,081	-681 Reduced 2.44%	27,180 $1.58 Million
Q2 2023 Nov 13, 2023	BUY	$63.71 - $70.74 $75,432 - $83,756	1,184 Added 4.44%	27,861 $1.78 Million
Q2 2023 Aug 10, 2023	BUY	$63.71 - $70.74 $75,432 - $83,756	1,184 Added 4.44%	27,861 $1.78 Million

Q1 2023 Nov 13, 2023	BUY	$65.71 - $74.53 $88,379 - $100,242	1,345 Added 5.31%	26,677 $1.85 Million
Q1 2023 May 16, 2023	BUY	$65.71 - $74.53 $88,379 - $100,242	1,345 Added 5.31%	26,677 $1.85 Million
Q4 2022 Nov 13, 2023	SELL	$68.48 - $81.09 $173,185 - $205,076	-2,529 Reduced 9.08%	25,332 $1.82 Million
Q4 2022 Feb 03, 2023	SELL	$68.48 - $81.09 $129,221 - $153,016	-1,887 Reduced 6.93%	25,332 $1.82 Million
Q3 2022 Oct 26, 2022	SELL	$0.13 - $76.84 $4 - $2,612	-34 Reduced 0.12%	27,219 $1.94 Million
Q2 2022 Aug 08, 2022	BUY	$72.62 - $79.98 $24,255 - $26,713	334 Added 1.24%	27,253 $2.1 Million
Q1 2022 May 12, 2022	BUY	$61.48 - $73.72 $10,021 - $12,016	163 Added 0.61%	26,919 $1.97 Million
Q4 2021 Jan 25, 2022	SELL	$53.63 - $62.52 $10,672 - $12,441	-199 Reduced 0.74%	26,756 $1.67 Million
Q3 2021 Nov 04, 2021	SELL	$59.17 - $69.31 $74,021 - $86,706	-1,251 Reduced 4.44%	26,955 $1.6 Million
Q2 2021 Aug 09, 2021	SELL	$61.91 - $67.42 $104,751 - $114,074	-1,692 Reduced 5.66%	28,206 $1.89 Million
Q1 2021 May 14, 2021	SELL	$59.34 - $66.74 $231,544 - $260,419	-3,902 Reduced 11.54%	29,898 $1.89 Million
Q4 2020 Feb 09, 2021	SELL	$57.74 - $65.43 $44,171 - $50,053	-765 Reduced 2.21%	33,800 $2.1 Million
Q3 2020 Nov 05, 2020	SELL	$57.43 - $63.64 $53,811 - $59,630	-937 Reduced 2.64%	34,565 $2.08 Million
Q2 2020 Jul 30, 2020	BUY	$54.82 - $64.09 $476,659 - $557,262	8,695 Added 32.44%	35,502 $2.09 Million
Q1 2020 May 08, 2020	SELL	$46.4 - $67.43 $956,536 - $1.39 Million	-20,615 Reduced 43.47%	26,807 $1.5 Million
Q4 2019 Feb 06, 2020	BUY	$49.21 - $64.19 $310,416 - $404,910	6,308 Added 15.34%	47,422 $3.04 Million
Q3 2019 Oct 29, 2019	BUY	$42.77 - $50.71 $714,087 - $846,654	16,696 Added 68.38%	41,114 $2.08 Million
Q2 2019 Aug 29, 2019	SELL	$44.62 - $49.34 $88,258 - $97,594	-1,978 Reduced 7.49%	24,418 $1.11 Million
Q1 2019 May 13, 2019	SELL	$45.12 - $53.8 $402,741 - $480,218	-8,926 Reduced 25.27%	26,396 $1.26 Million
Q4 2018 Feb 15, 2019	BUY	$48.76 - $63.23 $127,507 - $165,346	2,615 Added 8.0%	35,322 $1.84 Million
Q3 2018 Nov 14, 2018	BUY	$55.19 - $62.25 $564,483 - $636,693	10,228 Added 45.5%	32,707 $2.03 Million
Q2 2018 Aug 14, 2018	BUY	$50.53 - $62.98 $757 - $944	15 Added 0.07%	22,479 $1.24 Million
Q1 2018 May 15, 2018	BUY	$59.92 - $68.98 $50,332 - $57,943	840 Added 3.88%	22,464 $1.42 Million
Q4 2017 Feb 12, 2018	BUY	$59.94 - $65.35 $853,665 - $930,714	14,242 Added 192.93%	21,624 $1.33 Million
Q3 2017 Nov 14, 2017	SELL	$55.23 - $63.74 $49,707 - $57,366	-900 Reduced 10.87%	7,382 $471,000
Q2 2017 Aug 11, 2017	BUY	N/A	8,282	8,282 $462,000

Others Institutions Holding BMY

# of Institutions

2,553

Shares Held

1.49B

Call Options Held

25.9M

Put Options Held

20M

View Full List

About BRISTOL MYERS SQUIBB CO

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $84.3B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

More about BMY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Hancock Whitney Corp, based on Form 13F filings with the SEC.

News

Stay updated on Hancock Whitney Corp with notifications on news.

Account

Hancock Whitney Corp Bristol Myers Squibb CO Transaction History